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ABSTRACT
The ﬁlamentous fungus Ashbya gossypii has long been considered a paradigm of the White
Biotechnology in what concerns riboﬂavin production. Its industrial relevance led to the
development of a signiﬁcant molecular and in silico modeling toolbox for its manipulation. This,
together with the increasing knowledge of its genome and metabolism has helped designing
effective metabolic engineering strategies for optimizing riboﬂavin production, but also for
developing new A. gossypii strains for novel biotechnological applications, such as production of
recombinant proteins, single cell oils (SCOs), and ﬂavour compounds. With the recent availability
of its genome-scale metabolic model, the exploration of the full biotechnological potential of
A. gossypii is now in the spotlight. Here, we will discuss some of the challenges that these emerging
A. gossypii applications still need to overcome to become economically attractive and will present







Ashbya gossypii (syn. Eremothecium gossypii) is a
highly ﬂavinogenic mold of the Saccharomycetaceae
family that has been extensively exploited for the pro-
duction of riboﬂavin (vitamin B2). Genetically
improved A. gossypii strains have been used since
1990 for the industrial production of this vitamin by
the chemical company BASF.1 Given the biotechno-
logical relevance of this ﬁlamentous fungus, signiﬁcant
efforts have been made in the last decades to develop
molecular and systems biology tools for its engineer-
ing, which altogether allowed to greatly improve the
productivity of the initial industrial strains developed
by classical mutagenesis techniques.2,3 The success of
this strain improvement program ultimately led to the
replacement at the industrial level of the chemical
riboﬂavin production process by the biotechnological
one, as the later became economically and ecologically
more feasible than the ﬁrst.1-3 Thus, this biotechnolog-
ical process with A. gossypii became a paradigm of the
sustainable White Biotechnology business model.
Although the industrial production of riboﬂavin
has come a long way, the recent advances in the ﬁeld
of systems biology for A. gossypii2,4-7 have shown that
the carbon ﬂux of this fungus toward riboﬂavin pro-
duction can be further improved.8,9 Moreover, the in
silico modeling tools that recently became available for
A. gossypii are also boosting the emergence of other
commercially valuable biotechnological applications
for this fungus, such as SCO production,10 ﬂavour
compounds production11-13 and also recombinant
protein production14,15 (Fig. 1).
While important advances have been accomplished
in what concerns these new A. gossypii applications
(Table 1), several challenges still need to be overcome
until these emerging applications can follow the suc-
cessful commercial track of riboﬂavin production.
Here, we will pin point some of these challenges and
will indicate future perspectives for these new A. gossy-
pii biotechnological applications.
Recombinant protein production
Among the new biotechnological applications for
which A. gossypii has been explored, recombinant pro-
tein production was the ﬁrst to emerge, motivated by
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several interesting features presented by this fungus,
such as: (a) ability to secrete native and heterologous
enzymes to the extracellular medium and to recognize
signal peptides of other organisms as secretion sig-
nals;15-17,23 (b) ability to perform protein post-transla-
tion modiﬁcations, such as glycosylation (producing
N-glycans similar in extent to those produced by
nonconventional yeast, such as Pichia pastoris) and
other modiﬁcations required for the bioactivity and
stability of recombinant proteins;16,17,24 (c) secretion
of low amount and variety of native proteins and neg-
ligible extracellular protease activity, which facilitates
downstream processing and recovery of low- and
medium-value secreted products, as these are less
Figure 1. Main products and metabolic reactions involved in the new biotechnological applications for which A. gossypii has been
explored. Dashed arrows indicate several reactions. DHAP, dihydroxy-acetone-phosphate; PRPP, phosphoribosyl pyrophosphate; IMP,
inosine-50-phosphate; GMP, guanosine-50-phosphate; GTP, guanosine-50-triphosphate.
Table 1. Production levels of some biotechnological relevant compounds produced by A. gossypii. The production levels of these
bioproducts by other microorganisms are also presented for comparison.
Species Product Genetic Background Culture Conditions Optimization Production levels Reference(s)
Recombinant proteins
A. gossypii Endoglucanase I Engineered No Up to 400 mmol/min.L 14,16
Saccharomyces cerevisiae Engineered No Up to 1000 mmol/min.L
A. gossypii b-galactosidase Engineered No Up to 1127 U/mL 17
Aspergillus niger Wild Type No Up to 3000 U/mL
SCOs
A. gossypii Single cell oil Engineered No Up to 70% of CDW 10
Yarrowia lipolytica Engineered Yes Up to 88% of CDW
A. gossypii Linoleic acid Engineered No 16% of total fatty acids 18
Y. lipolytica Wild type Yes 31% of total fatty acids 19
Flavour compounds
A. gossypii 2-phenylethanol Wild type No Up to 0.2 g/L 11
S. cerevisiae and Kluyveromyces marxianus Wild type Yes 0.25 – 20 g/L 20
A. gossypii Isoamyl alcohol Engineered No 0.5 – 0.6 g/L 11
S. cerevisiae Mutants Yes 0.4 – 0.5 g/L 21
A. gossypii Inosine Engineered No Up to 2.2 g/L 12,13
Bacillus subtilis Engineered No 6 – 7 g/L
A. gossypii Guanosine Engineered No Up to 0.14 g/L 12
Bacillus amyloliquefaciens Engineered mutant No Up to 13.5 g/L 22
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likely to be contaminated or degraded by native pro-
teins;15,16 (d) high genetic tractability, with a rich
molecular toolbox available for its manipulation;2,25
(e) remarkable genomic similarities with the budding
yeast S. cerevisiae, which facilitates the transfer of
accumulated know-how on this model yeast genetics
and cell biology to A. gossypii;2 (f) ability to grow in
cheap waste-derived substrates to high cell densi-
ties;26-27 (g) and demonstrated suitability for use in
large-scale industrial fermentation processes.1,3
While the ﬁrst heterologous proteins secreted by A.
gossypii (endoglucanase I (EGI) and cellobiohydrolase
I (CBHI) from Trichoderma reesei) were produced at
very low yields,16 latter on it was found that the
expression vector and promoter (from ScPGK1) ini-
tially used were inefﬁcient in promoting gene overex-
pression in A. gossypii.14,15,17 After removal of the
ScADH1 terminator sequence from the initial vector
(because it had been reported to display autonomous
replicating sequence activity in A. gossypii), a 2-fold
improvement in EGI production was achieved.14 Simi-
lar enhancements were also obtained by random
mutagenesis of the recombinant A. gossypii EGI-pro-
ducing strain.14 However, when the ScPGK1 promoter
was substituted by the native A. gossypii promoters
from AgTEF and AgGPD, the recombinant secretion
of a b-galactosidase from A. niger was improved by up
to 8-fold, thus leading to production levels (248 to
1127 U/mL) within the range of those reported for
unmodiﬁed A. niger strains (152 to 3000 U/mL).17
Interestingly, when glycerol was used instead of glu-
cose as carbon source, the recombinant production of
b-galactosidase by A. gossypii was 1.5-fold higher,17
which indicates that further optimization of culture
media and operation conditions will most likely
enhance even more recombinant protein production
by A. gossypii. Therefore, A. gossypii shows up as
promising recombinant protein production host. Nev-
ertheless, the potential of this fungus as a host for het-
erologous protein production is still underexplored.
The screening for better promoters and secretion sig-
nal sequences, together with the development of better
expression strategies, preferably through the integra-
tion of stable expression cassettes, hold the potential
to maximize heterologous protein secretion by A. gos-
sypii, ultimately clarifying whether A. gossypii will ever
be able to meet the demands of the biotechnology
industry in what concerns recombinant protein
production.
Optimization of the A. gossypii natural
metabolism
The natural ability of A. gossypii to overproduce riboﬂa-
vin is well known, but this fungus also has a naturally
attractive metabolism in what concerns biolipid accumu-
lation,10 nucleosides excretion12 and aroma alcohols for-
mation.11 With the increasing number of genomic,
transcriptomic, proteomic, ﬂuxomic and bioinformatic
data that became available for A. gossypii in the last
years,2,4-7,15 several systems metabolic engineering strate-
gies have been designed and implemented to improve its
metabolic ﬂux toward the production of these commer-
cially valuable bioproducts.10-13
SCO production
Microbial lipids (often referred to as SCOs) constitute
a promising renewable source for the sustainable pro-
duction of biodiesel and other value-added oleochemi-
cals, as they do not affect food costs and security, and
can be obtained in large amounts by fermentation of
waste-derived substrates under controlled conditions
that are not dependent on climate or soil conditions.
SCOs can also be interesting as food supplements, as
some microorganisms are able to produce high-value
polyunsaturated fatty acids (PUFAs), such as those
belonging to the omega-3 and omega-6 families.
Although not considered an oleaginous microor-
ganism, A. gossypii was metabolically engineered to ﬁt
the requisites of a candidate for SCO production,
being one of the engineered strains (pox1D) able to
accumulate up to 70% of its dry cell weight (CDW) as
lipids.10 A. gossypii naturally produces mostly unsatu-
rated fatty acids: 55% oleic acid, 20% palmitoleic acid,
14% palmitic acid, 3% linoleic acid, 1.1% stearic, and
around 4% of very long-chain fatty acids.18 Since the
potential applications of SCOs are strictly connected
with the fatty acid proﬁle of the strain, metabolic engi-
neering was also applied to the A. gossypii elongase
and desaturase systems and some of the generated
strains were able to accumulate more linoleic acid
(which is a precursor of both omega-3 and omega-6
PUFAs; strains GPD-DES589 and A586), cerotic acid
(which is the main component of high-melting point
waxe; strain GPD-ELO586), or nervonic acid (which is
a major component of high-temperature lubricants
and engineered nylons, and also important for phar-
maceuticals and nutraceuticals; strain GPD-ELO624),
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or presented optimized features for the production of
biodiesel (strains elo586D and elo624D).18,28
Despite the substantial improvements achieved in
biolipid production with A. gossypii, both in terms of
yield as in enrichment in desired fatty acids, given the
importance of the cost/beneﬁt ratios in microbial bio-
technology processes, production costs must be mini-
mized as much as possible. Therefore, is important to
obtain good product yields and productivities from
low cost substrates, such as raw carbon sources
derived from industrial wastes. Given that in sugar-
based media A. gossypii strains were only able to pro-
duce up to 9% of their CDW as lipids,10 biolipid pro-
duction from waste/low-cost sugars must be greatly
improved both by medium optimization and strain
engineering (this may also include expanding the
range of substrates that A. gossypii can degrade and
increasing its resistance to toxic compounds present
in cheap raw materials). On the other hand, given the
increased rate of lipid accumulation by A. gossypii in
oil-containing media, the conversion of cheap oils
into high-value oils should be further explored. Addi-
tionally, future studies should also consider engineer-
ing strains with improved fatty acid secretion to
facilitate their recovery and reduce extraction costs.
Nucleoside production
As a riboﬂavin overproducer, A. gossypii displays a
naturally enhanced metabolic ﬂux through the purine
biosynthetic pathway, the central pathway for purine
nucleotide and nucleoside biosynthesis (Fig. 1).
Recently, several A. gossypii wild strains were screened
for their natural ability to produce purine nucleosides
and all were found to excrete high levels of inosine to
the culture medium, and also guanosine.12 These
nucleosides are very appreciated by the food industry,
as they are the direct precursors of the umami ﬂavour
enhancers IMP and GMP, and have various beneﬁcial
effects associated to them, such as antioxidant and
immunomodulatory properties.12,13
Through rational metabolic engineering of key
genes in the A. gossypii purine biosynthetic pathway,
inosine excretion could be increased by up to 150-
fold.13 This particular improvement was achieved by
disrupting only 2 genes: AgADE12, which encodes the
enzyme that catalyzes the conversion of IMP into
adenylosuccinate, and AgPNP1, which encodes the
enzyme that catalyzes the conversion of the
nucleosides inosine and guanosine into the nucleo-
bases hypoxanthine and guanine, respectively. Of all
the metabolic engineering strategies tested, this was
the most efﬁcient in redirecting the metabolic ﬂux of
A. gossypii toward the production of inosine, allowing
the obtainment of up to 2.2 g/L inosine in rich
medium containing 40 g/L glucose.9,12,13 Guanosine
excretion was also increased in this strain (Dade12/
Dpnp1), but only by up to 2-fold.13
In view of these results, A. gossypii became the ﬁrst
eukaryotic microorganism presenting good potential for
the industrial production of inosine, which traditionally
has been accomplished with B. subtilis and Escherichia
colimodiﬁed strains. However, in order to reach the ino-
sine excretion levels reported for the best engineered bac-
terial strains (6–7 g/L), additional manipulations of the
central metabolism and of the purine salvage pathway, of
global metabolic regulators, and of transporters may be
necessary.9,12.13 On the other hand, given that the deletion
(or underexpression) of the AgADE12 gene efﬁciently
redirected the metabolic ﬂux toward the GMP purine
branch, future studies should explore the production of
other GMP-derived metabolites, such as folates (vitamin
B9), by these strains.8,9,12,13
Aroma alcohols production
Many microorganisms naturally synthesize ﬂavour
compounds as secondary metabolites during fermenta-
tion on nutrients that include precursors or intermedi-
ates for their biosynthesis/bioconversion, as is the case
of A. gossypii.11 Traditionally, complex mixtures of aro-
matic alcohols (known as fusel alcohols) and esters have
been obtained as part of food or beverage fermentation
processes (e.g. cheese, beer, wine) at low concentrations,
where they contribute to the overall ﬂavour of the fer-
mented products.29 The strong interest of the fermented
food and beverages sector in new products with interest-
ing ﬂavour/aroma perceptions has supported the con-
tinuous search for novel producing organisms.2,11
Moreover, the increasing demand for natural ﬂavour
compounds such as isoamyl alcohol (banana/fruity
aroma) and 2-phenylethanol (rose/ﬂower aroma),
which can be produced from amino acids via the Ehrlich
pathway in microbial-based bioconversion processes
(Fig. 1), has been boosting the design of new strains and
fermentation processes capable of generating high
amounts of speciﬁc ﬂavour compounds for subsequent
puriﬁcation and use as additives.29
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Recently, the potential of A. gossypii for ﬂavour
compounds production was explored and the analysis
of its aroma alcohol proﬁle revealed that A. gossypii
produces large amounts of isoamyl alcohol and 2-phe-
nylethanol.11 Through overexpression of the
AgARO80 gene, which encodes a transcriptional regu-
lator for some of the Ehrlich pathway ARO-genes, iso-
amyl alcohol and isobutanol production could be
increased by 2.5-fold, whereas the levels of 2-phenyle-
thanol remained unchanged, possibly due to phenylal-
anine limitation in the culture medium.11 This
modiﬁcation also resulted in a 50% increase in overall
volatile compound production.11
Envisioning the development of commercial produc-
tion of 2-phenylethanol by yeast, some of the organisms
identiﬁed as possibly good sources of natural 2-phenyle-
thanol have been the target of optimization strategies that
have included the overexpression/deletion of other ARO-
genes.20 Therefore, future attempts to improve 2-phenyl-
ethanol production by A. gossypii may follow similar
strategies. Nevertheless, the use of metabolic engineering
approaches to improve yields of this compound is very
sensitive due to the complexity of the hosts’ metabolic
regulation. On the other hand, one of the major bottle-
necks associated with the production of high amounts of
these aromatic alcohols is their toxicity to the producer
strains,20,29 and so it may be necessary to consider engi-
neering strains with improved resistance to these
compounds.
Optimization of production conditions
Although signiﬁcant advances have been given in terms
of A. gossypii strain engineering for new biotechnological
applications, rational engineering and systems biology
will necessarily have to be combined with process devel-
opment and optimization in order to drive these new
A. gossypii applications through the successful commer-
cial track of riboﬂavin production.
While some improvements have been achieved in the
production of recombinant proteins, SCOs and inosine
by changing the origin/concentration of the carbon
source used in the fermentation medium,13,17,18 system-
atic optimization of the culture medium composition or
of fermentation conditions has not yet been assessed.
Therefore, it is foreseen that much can still be improved
in terms of strain productivity and product yields by opti-
mization of production conditions. But to make these
biotechnological processes commercially attractive, when
designing optimization strategies, efforts must be made
to reduce production costs to aminimum.
A. gossypii already possesses interesting characteris-
tics that confer it biotechnological advantages in terms
of production costs, such as (a) ability to grow by pel-
let fermentation, which reduces culture viscosity and
improves mixing and mass transfer, saving both costs
and energy,10 (b) at late growth phases or at low tem-
perature its hyphae undergoes autolysis, thus facilitat-
ing the downstream recovery of intracellular
metabolites,2 and (c) its biomass can be easily sepa-
rated from the culture broth by gravity sedimentation
or simple ﬁltration, which are very convenient separa-
tion process for use at industrial scale.10
On the other hand, one important way to lower pro-
duction costs is by using inexpensive carbon sources and
nutrients, preferably fromwidely available industrial resi-
dues. In this sense, the known ability of A. gossypii to
grow in some industrial by-products and low-cost
oils2,26,27 may be easily explored. Additionally, the expan-
sion of the carbon source range thatA. gossypii can utilize
by metabolic engineering (e.g., xylose utilization) may
open new perspectives in terms of the raw substrates that
may be used in these processes (such as lignocellulosic
biomass).
Solid-state fermentation (SSF) has also been used as a
mean to improve the economical feasibility of secondary
metabolite production processes.29 The main advantages
of SSF over submerged fermentation are: (a) higher
energy efﬁciency and reduced water consumption, (b)
lower cost due to efﬁcient utilization and value-addition
of solid wastes, and (c) generally higher product yields
and better product characteristics.29 With this in mind,
and given that ﬁlamentous fungi generally have a higher
metabolic potential in SSF,29 future studies should assess
the production of secondary metabolites (e.g. 2-phenyle-
thanol) byA. gossypii using this cultivationmode.
Concluding remarks
Over the past few years, with the expansion of the A.
gossypii molecular and in silico modeling toolbox, the
potential of this fungus as a cell factory has been thor-
oughly explored. Supported by the increasingly high
number of genomic,5,30 transcriptomic,4,15 proteo-
mic15 and ﬂuxomic7 data that is becoming available
for A. gossypii, in the forthcoming years systems biol-
ogy is expected to continue driving the improvement
of current and the emergence of novel
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biotechnological applications for this fungus. The (re-)
construction and investigation of progressively more
accurate genome-scale metabolic models will certainly
lead to the identiﬁcation of novel targets for A. gossypii
metabolic engineering; and to facilitate and speed up
systems metabolic engineering approaches, the devel-
opment of efﬁcient synthetic biology tools for use in
A. gossypii will be necessary.
While the existing molecular toolbox has been
effective in generating stable A. gossypii strains with
improved traits for pinpointed biotechnological appli-
cations, the development of new and more ﬂexible
tools will be crucial to boost the engineering capabili-
ties of this fungus. In this regard, the establishment of
ﬂexible and highly efﬁcient genome editing methods
(e.g., CRISPR-Cas9 system) for A. gossypii engineering
is of great interest. Also, as the number of character-
ized promoters currently available for A. gossypii is
limited, the screening, identiﬁcation and design of
other promoters with desired characteristics will settle
the basis for the development of new and more ﬂexible
gene expression tools.
On the other hand, the systematic exploration of this
fungus natural biodiversity will help identify new strains
with better biotechnological potential, and should there-
fore be considered as a standard procedure in the devel-
opment of novel applications. However, the success of
any emerging biotechnological application will strongly
depend on the combination of strain and process optimi-
zation. In this context, the development of cost-effective
high-throughput screening methodologies will be of
upmost importance to guarantee the rapid screening and
characterization of wild, mutant and engineered strains
under different process conditions.
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